Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
Ready to participate?
Review the details below, then apply to join this clinical trial.
At a Glance
Age
18 – 65
Sex
Any
Trial phase
Phase 2
Study type
Interventional
Purpose
Treatment
Participants needed
24 (estimated)
Sponsor
Alnylam Pharmaceuticals · Industry
Who this trial is looking for
This trial is looking for adults with type 2 diabetes. Participants will receive a single dose of ALN-4324 to see how it affects their insulin sensitivity.
Are You a Good Fit for This Trial?
Must be takingMetforminSGLT2iDPP4i
You may be able to join if
I have been diagnosed with type 2 diabetes
I am an adult
My BMI is between 23 and 39.9
My hemoglobin A1c is between 6.5% and 10.5%
I am taking a stable dose of metformin, SGLT2i, or DPP4i
You may not be able to join if
I have a significant medical condition that affects my safety
I am taking medications that interfere with glucose or insulin metabolism
Summarized in plain language from this trial's official eligibility criteria.
The full criteria are further down this page — only the research team can
confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
The purpose of this study is to evaluate the effect of a single dose of ALN-4324 on whole-body insulin sensitivity in participants with T2DM
Trial Locations
Loading…
Loading trial locations…
Facility
City
State
Country
Status
Eligibility Criteria
Inclusion Criteria:
* Is an adult patient with a confirmed diagnosis of T2DM
* Has a body mass index (BMI) of ≥23 kg/m\^2 to ≤39.9 kg/m\^2
* Has a hemoglobin A1c (HbA1c) ≥6.5% to \<10.5%
* Is on a stable dose of metformin, sodium-glucose cotransporter 2 inhibitor (SGLT2i), or dipeptidyl peptidase-4…
Inclusion Criteria:
* Is an adult patient with a confirmed diagnosis of T2DM
* Has a body mass index (BMI) of ≥23 kg/m\^2 to ≤39.9 kg/m\^2
* Has a hemoglobin A1c (HbA1c) ≥6.5% to \<10.5%
* Is on a stable dose of metformin, sodium-glucose cotransporter 2 inhibitor (SGLT2i), or dipeptidyl peptidase-4 inhibitor (DPP4i)
Exclusion Criteria:
* Has any clinically significant concomitant disease, medical condition, or abnormal laboratory finding that could compromise participant safety or confound interpretation of study results
* Receiving therapies known to interfere with glucose or insulin metabolism other than current treatment for T2DM or birth control methods
Note: other protocol defined inclusion/exclusion criteria apply
Picking one helps us show the most relevant trials first.
Your results are loading in the background — you can
change this any time from the results page.
Set your location to continue
Find My Trials uses your location to surface clinical trials near you.
Add your city or zip code to your profile and try again.
